Skinvisible, Inc. (SKVI) and Quoin Poised to Tackle Opioid Crisis with Alternative Pain Therapies
A possible larger role for leading drug manufacturers, and the resulting opioid epidemic, is met with increased public and government demands for alternative therapies The Skinvisible and Quoin merger, with expected completion in 2018, will create an enterprise positioned to disrupt the $6 billion U.S. opioid market by producing and delivering non-opioid alternatives for pain management Quoin’s QRX001 is slated to provide alternative and effective pain management in the post-surgical setting, where 50 percent of opioid addictions start A recent article by the Washington Post (http://cnw.fm/J40mp) addressed the opioid crisis, suggesting a larger role by leading pharmaceutical drug manufacturers than…
